Pharmaceutical salts of piroxicam and meloxicam with organic counterions

Loading...
Thumbnail Image
Files
cg-2022-007227_revision2.pdf(2.98 MB)
Accepted Version
cg2c00722_si_001.pdf(2.65 MB)
Supporting Information
Date
2022-10-21
Authors
Huang, Shan
Venables, Dean S.
Lawrence, Simon E.
Journal Title
Journal ISSN
Volume Title
Publisher
ACS Publications
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Piroxicam (PRM) and meloxicam (MEL) are two nonsteroidal anti-inflammatory drugs, belonging to the Biopharmaceutics Classification System Class II drugs. In this study, six novel pharmaceutical salts of PRM and MEL with three basic organic counterions, that is, 4-aminopyridine (4AP), 4-dimethylaminopyridine (4DMP), and piperazine (PPZ), were prepared by both slurrying and slow evaporation. These salts were characterized by single-crystal and powder X-ray diffraction, thermal analysis, and Fourier transform infrared spectroscopy. All six salts, especially MEL-4DMP and MEL-4AP, showed a significantly improved apparent solubility and dissolution rate in sodium phosphate solution compared with the pure APIs. Notably, PRM-4AP and PRM-4DMP salts exhibited enhanced fluorescence, and the PRMPPZ salt showed weaker fluorescence compared with that of pure PRM due to different luminescence mechanisms.
Description
Keywords
Aggregation-induced emission , Co-crystals , Solid-state , Quantitative analysis , Structural analysis , Chemical stability , Melt extrusion , Hydrogen bond , Solubility , Cocrystals
Citation
Huang, S., Venables, D. S. and Lawrence, S. E. (2022) 'Pharmaceutical salts of piroxicam and meloxicam with organic counterions', Crystal Growth and Design, 22(11), pp. 6504-6520. doi: 10.1021/acs.cgd.2c00722
Copyright
© 2022, American Chemical Society. This document is the Accepted Manuscript version of a Published Work that appeared in final form Crystal Growth and Design, 22(11), pp. 6504-6520, after technical editing by the publisher. To access the final edited and published work see: https://doi.org/ 10.1021/acs.cgd.2c00722